Dr. Leonard S. Marks, MD

Dr. Marks practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Marks' NPI, 1811037450, was assigned on February 6, 2007. Dr. Marks graduated from University of Texas Medical Branch at Galveston in 1969. Dr. Marks holds California license C34148.

Dr. Marks' primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Marks' primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Marks is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Marks to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Marks practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Marks' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Marks is board certified in urology by the American Board of Urology. Dmand AI has Dr. Marks' licenses on file in 2 states: California and Texas.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, prostate cancer and urinary endoscopy among the conditions Dr. Marks treats.

CMS data shows 8,230 Medicare services from Dr. Marks across 19 procedure codes in 2024, for 1,015 Medicare patients. Medicare paid $304,180 for them.

CMS counts 1,015 Medicare patients who saw Dr. Marks in 2024. The largest group is 65 to 74, with 543 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Marks' median patient age at 71, with 0% women.

In 2024, Dr. Marks wrote 442 Medicare Part D claims for 164 patients. 93% of them were for generic drugs. CMS names the drug for 388 of them, across 8 drugs with 11 or more claims each, at $32,859 in total drug cost. In 2023, CMS named 237 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Marks for performance year 2024, reported as part of a group. Dr. Marks accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Marks as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 31 papers to Dr. Marks, published from 2011 to 2019. 2011 was the busiest year, with 2. Dr. Marks' most frequent co-authors are Ely Richard Felker, MD, Anthony Eugene Sisk, DO and Robert Evan Reiter, MD.

Dmand AI links Dr. Marks to 5 clinical trials, 2 of them phase 2/3 studies. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urinary Bladder, Overactive. Jonsson Comprehensive Cancer Center sponsors the most, 2.

CMS Open Payments shows 35 general payments to Dr. Marks from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 45% of the total. Hitachi Healthcare Americas Corp. paid the most, $545.

Dmand AI lists 6 awards for Dr. Marks, most recently Research Award in 2001.

Dr. Marks graduated from University of Texas Medical Branch at Galveston in 1969.

Dr. Marks is in network with 14 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.